FTN Midwest Downgrades Alpharma (ALO) to Neutral
More News related to ALO
- American Electric Power Awards Alstom Power Contracts Worth Over USD 100 Million (EUR70 Million) to Add Power and Reliability to Its DC Cook 1 and Conesville 4 Power Plants in the US
- Alstom and Schlumberger Seal a Joint Agreement to Develop Carbon Capture & Storage Readiness Studies For Power Plants
- Video: AEP and Alstom Commission First of Its Kind Carbon Capture and Sequestration (CCS) Project
- Pilot Project Captures 90% of CO2
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
More News related to Downgrades
- Shields & Co. Downgrades ALLETE, Inc. (ALE) to Hold
- Scotia Capital Downgrades Grupo Aeroportuario del Centro (OMAB) to Sector Perform
- Goldman Sachs Upgrades Bradesco and Banco do Brasil; Downgrades Bancolombia
- Wedbush Downgrades Burger King (BKC) to Underperform
- Morgan Stanley Upgrades Safeway (SWY), Downgrades SUPERVALU (SVU)
FTN Midwest downgrades Alpharma (NYSE: ALO) from Buy to Neutral.
Alpharma, Inc. develops, manufactures, and markets pharmaceutical products for humans and animals worldwide.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
